In order to outline practical orientation points, we retrospectively reviewed the medical records of MM patients from our institution treated with BRAF/MEK inhibitors and PD1 blockades in order to define the incidence of oligoprogression defined as a condition characterized by a progression of a solitary or few (≤3) metastases in a single site or organ suitable of local treatment, while all the rest of the disease had already responded or was stable to the ongoing systemic therapy. Here, MAP2K7 is linked to Miyoshi myopathy.